AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CYNATA THERAPEUTICS LTD

0.385

+0.0051.32%

Volume:567.78K

Turnover:223.95K

Market Cap:91.42M

PE:-8.40

High:0.410

Open:0.380

Low:0.380

Close:0.380

52wk High:0.435

52wk Low:0.140

Shares:237.45M

Float Shares:175.62M

Volume Ratio:2.63

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.046

EPS(LYR):-0.046

ROE:-142.29%

ROA:-77.08%

PB:15.28

PE(LYR):-8.40

Loading ...

Overview Company News Filings

Concept

Novel Coronavirus Treatment+0.76%

Pharmaceutical Companies+1.74%

Capital Flow

Inflow:

Outflow:

News

ASX Opportunities: Aroa Biosurgery And 2 Other Promising Penny Stocks

Simply Wall St.

Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says

MT Newswires Live

BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses

Cynata Completes Patient Enrolment in Phase 2 aGvHD Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CYP.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","market":"AU","secType":"STK","nameCN":"CYNATA THERAPEUTICS LTD","latestPrice":0.385,"timestamp":1770700320000,"preClose":0.38,"halted":0,"volume":567779,"delay":0,"changeRate":0.013157894736842117,"nameEN":"CYNATA THERAPEUTICS LTD","floatShares":175624818,"shares":237454369,"eps":-0.045818,"marketStatus":"Closed","change":0.005,"latestTime":"02-10 16:12:00 AEDT","open":0.38,"high":0.41,"low":0.38,"amount":223954,"amplitude":0.078947,"askPrice":0.4,"askSize":25338,"bidPrice":0.385,"bidSize":27999,"shortable":3,"etf":0,"ttmEps":-0.045818,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.38,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":2.626109,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","floatShares":175624818,"roa":"-77.08%","roe":"-142.29%","lyrEps":-0.045818,"volumeRatio":2.626109,"shares":237454369,"dividePrice":0,"high":0.41,"amplitude":0.078947,"preClose":0.38,"low":0.38,"week52Low":0.14,"pbRate":"15.28","psRate":"48.50","week52High":0.435,"institutionHeld":0,"latestPrice":0.385,"committee":0.04989,"eps":-0.045818,"divideRate":0,"volume":567779,"delay":0,"ttmEps":-0.045818,"open":0.38,"prevYearClose":0.345,"prevWeekClose":0.345,"prevMonthClose":0.32,"prevQuarterClose":0.345,"fiveDayClose":0.335,"twentyDayClose":0.375,"sixtyDayClose":0.25,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-12-15","symbol":"CYP.AU","defaultRemindTime":1607986800000,"type":"split","dateTimestamp":1607950800000,"forFactor":2147483647,"toFactor":2147483647,"ratio":0.997023}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYP.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610505033","title":"ASX Opportunities: Aroa Biosurgery And 2 Other Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2610505033","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610505033?lang=en_us&edition=fundamental","pubTime":"2026-02-09 03:02","pubTimestamp":1770577340,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a challenging period, with a significant downturn influenced by global market pressures and recent tech selloffs. Despite the turbulence, investors often seek opportunities in penny stocks, which can offer unique value propositions when backed by strong financials. These smaller or newer companies may present potential for growth and stability, making them intriguing options for those looking to uncover hidden gems in the stock market.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/asx-opportunities-aroa-biosurgery-and-2-other-promising-penn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/asx-opportunities-aroa-biosurgery-and-2-other-promising-penn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BVR.AU","MTO.AU","BK7077","BK7055","IGL.AU","ARX.AU","BK7128","BK7050","WAF.AU","BK7104","BK7508","BK7501","BK7503","BK7062","BK7016","BK7095","BK7506","AAL.AU","MXI.AU","VRS.AU","SSM.AU","PPS.AU","DSK.AU","AEF.AU","BK7067","BK7143","CYP.AU","BK7045"],"gpt_icon":0},{"id":"2591967429","title":"Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591967429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591967429?lang=en_us&edition=fundamental","pubTime":"2025-12-16 11:12","pubTimestamp":1765854732,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4218","BK4539","BK4181","HST","LENZ","BK4588","BK7508","BK4139","CYP.AU","BK4007","BK7067","BK4585","BK7501"],"gpt_icon":0},{"id":"2591694216","title":"BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2591694216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591694216?lang=en_us&edition=fundamental","pubTime":"2025-12-15 12:11","pubTimestamp":1765771917,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses** Shares of Cynata Therapeutics CYP.AX rise as much as 7.6% to A$0.285, their highest level since December 1** Stock set for its strongest trading session in over a week, if current trends hold** Stem cell and regenerative medicine maker says 65 patients have been enrolled in its Phase 2 clinical trial of CYP-001 in adults diagnosed with acute graft versus host disease ** aGvHD is a life-threatening complication where donor’s immune cells attack recipient's tissues ** Co says CYP-001 is designed to modulate immune system and improve both response rates and survival outcomes in aGvHD** Stock up 18.6% YTD, including session's moves  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL086:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2591594698","title":"Cynata Completes Patient Enrolment in Phase 2 aGvHD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591594698","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591594698?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:22","pubTimestamp":1765758165,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics Ltd. has announced the completion of patient enrolment in its Phase 2 clinical trial of CYP-001 for the treatment of acute graft versus host disease . The trial has enrolled 65 participants across the US, Europe, and Australia, who were randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary evaluation period will conclude in March 2026, with results expected in June 2026. The results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cynata Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3xwf7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CYP.AU","BK7501","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CYP.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","bkCode":"BK7501","id":"package_au_concept_xgzlg","changeRate":0.007617},{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.017447}]}}